ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2022年11月29日 11時00分
Source:
Eisai
エーザイ、「アリセプト(R)」について日本のレビー小体型認知症の適応に関する用法・用量の一部変更の承認について発表
東京, 2022年11月29日 - (JCN Newswire) - エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、自社創製のアルツハイマー型認知症・レビー小体型認知症治療剤「アリセプト(R)」（一般名：ドネペジル塩酸塩）について、日本におけるレビー小体型認知症に係る用法・用量に関する承認事項の一部変更を申請し、本日、承認されたことをお知らせします（変更内容は参考資料 1 に記載）。
今回の承認事項の一部変更は、本剤の「レビー小体型認知症における認知症症状の進行抑制」の効能・効果に関する再審査の結果、カテゴリー2*となったことに基づくものです。
当社は、今回のレビー小体型認知症に係る用法・用量の一部変更の承認を受け、引き続き、本剤の適正使用・安全性情報提供を最優先とした活動を行い、レビー小体型認知症の当事者様とそのご家族のニーズの充足とベネフィット向上に貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2022/news202282.html
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2024
Dec 27, 2024 11:00 JST
MHI Included in "World Index" of Dow Jones Sustainability Index for Second Consecutive Year
Dec 27, 2024 09:36 JST
TOYOTA GAZOO Racing to Exhibit at Tokyo Auto Salon 2025
Dec 26, 2024 17:11 JST
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam
Dec 26, 2024 12:00 JST
Mazda Production and Sales Results for November 2024
Dec 26, 2024 11:46 JST
MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development
Dec 26, 2024 09:47 JST
Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST
Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST
Nissan, Honda, and Mitsubishi Motors sign MOU on collaborative considerations
Dec 24, 2024 10:54 JST
GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China
Dec 24, 2024 10:23 JST
Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park
Dec 24, 2024 10:10 JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 23, 2024 17:22 JST
Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration
Dec 23, 2024 13:30 JST
Mitsubishi Motors Cumulative Production Reaches One Million Units in Indonesia
Dec 20, 2024 17:35 JST
Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport
Dec 20, 2024 17:24 JST
Toyota Launches Alphard and Vellfire PHEV Models in Japan
Dec 20, 2024 15:38 JST
6G Begins! Embarking on a New Journey of Global Interoperable Standards
Dec 19, 2024 16:50 JST
MI LNG Company to Change Corporate Name to MILES
Dec 19, 2024 13:49 JST
Two Honda 0 Series Prototype Models to Premiere at CES 2025
Dec 19, 2024 12:30 JST
More Latest Release >>
Related Release
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
12/23/2024 5:22:00 PM JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
11/28/2024 4:26:00 PM JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
11/26/2024 3:50:00 PM JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
11/20/2024 11:51:00 AM JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
11/20/2024 10:24:00 AM JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/15/2024 2:31:00 PM JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
11/5/2024 11:35:00 AM JST
More Press release >>